RSS

German Federal Institute for Drugs and Medical Devices (BfArM)

A Phase I study is set to be initiated by OncoArendi Therapeutics to assess the safety, tolerability and pharmacokinetics of its lead compound and novel drug candidate, OATD-01 for the treatment of asthma. Read more

News